Canada markets close in 3 hours 40 minutes

Affimed N.V. (AFMD)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
3.2700-0.0500 (-1.51%)
As of 12:20PM EDT. Market open.
Full screen
Loading interactive chart...
  • Zacks

    Affimed N.V. (AFMD) Reports Q2 Loss, Lags Revenue Estimates

    Affimed N.V. (AFMD) delivered earnings and revenue surprises of 22.22% and 4.22%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

  • GlobeNewswire

    Affimed Reports Second Quarter 2022 Financial Results and Highlights Recent Operational Progress

    AFM13 monotherapy: On track to report topline data of the registration-directed REDIRECT trial in the fourth quarter of 2022AFM13 combination with natural killer (NK) cells: On track to report updated data at a scientific conference in the fourth quarter of 2022AFM24: Studies continue to enroll; data updates expected at scientific conferences in the second half of 2022AFM28: Following interactions with FDA, strategic decision to focus early clinical development in non-U.S. jurisdictions; clinica

  • GlobeNewswire

    Affimed to Report Second Quarter 2022 Financial Results & Corporate Update on August 11, 2022

    HEIDELBERG, Germany, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it will release second quarter 2022 results and corporate update on Thursday, August 11, 2022. The Company will host a conference call at 8:30 a.m. Eastern Daylight Time. The conference call will be available via phone and webcast. To access the call,